Want to see TLRY full AI Analyst Report?
TLRY Stock Chart & Stats
$3.88
$0.15(3.87%)
At close: 4:00 PM EDT
$3.88
$0.15(3.87%)
Day’s Range― - ―
52-Week Range$3.67 - $23.20
Previous Close$4.04
Volume3.69M
Average Volume (3M)3.54M
Market Cap
$618.36M
Enterprise Value$780.77
Total Cash (Recent Filing)$231.27M
Total Debt (Recent Filing)$398.40M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Oct 01, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding136,203,580
10 Day Avg. Volume3,671,734
30 Day Avg. Volume3,536,097
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.38
Price to Sales (P/S)0.67
P/FCF Ratio-6.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.13Price Target Upside57.86% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$1.10B
Bulls Say, Bears Say
Bulls Say
International Cannabis Scale & CapacityRapid international volume growth and a large Portugal cultivation ramp materially increase supply-side scale, lower per-unit costs, and support durable medical export revenues. Higher utilization and multi-country momentum reduce dependence on any single market and enable sustained margin improvement as fixed costs spread.
Stronger Balance Sheet And LiquidityA sizable cash balance and near-zero net debt materially reduce refinancing risk and give management flexibility to fund operations, absorb integration costs, and pursue M&A or strategic initiatives without urgent external capital. This base supports execution while margins and cash flow recover.
Beverage & Distribution ExpansionThe BrewDog acquisition and a Carlsberg partnership deepen Tilray's beverage footprint and diversify revenue away from cannabis cycles. Expanded distribution and hospitality assets plus pharmacy reach in CC Pharma create multi-channel revenue streams that strengthen resilience and offer cross-sell and margin improvement potential.
Bears Say
Persistent Net Losses & Negative Free Cash FlowOngoing net losses and consistently negative free cash flow force reliance on external financing or equity issuance, constrain reinvestment, and hinder the path to self-sustaining profitability. Even with improvements, continued cash burn limits long-term return generation and increases dilution risk.
International Price Compression Reducing MarginsStructural price pressure in international markets erodes gross margins despite volume gains, limiting the company's ability to convert scale into profits. Persistent compression reduces buffer for rising input or integration costs and makes margin recovery dependent on competitive positioning and product mix improvements.
Working-capital Strain From BrewDog IntegrationLarge working-capital outflows tied to the BrewDog acquisition temporarily lock up liquidity and delay cash conversion from sales. Prolonged integration-related receivables and timing mismatches increase short-term financing needs and can impede reinvestment and margin improvement if not fully resolved over subsequent quarters.
Tilray News
TLRY FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was $3.67 and its highest was $23.20 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is $618.36M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Oct 01, 2026 which is in 59 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Jul 28, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.012 by -$0.418.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is -0.17.
How many shares outstanding does Tilray have?
Tilray has 136,203,580 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.012. Following the earnings report the stock price went down -0.993%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in TLRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.13 (57.86% Upside)
$6.13 (57.86% Upside)
Blogger Sentiment
Neutral
TLRY Sentiment 56%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 359.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 15.8%
Last 30 Days ▲ 15.8%
News Sentiment
Neutral
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.31%
Trailing 12-Months
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
TLRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful operational progress: record revenue and adjusted EBITDA, stronger liquidity (≈$235M cash) and near-zero net debt, substantial international cannabis and distribution growth, and strategic beverage expansion through the BrewDog acquisition and the Carlsberg partnership. At the same time, challenges remain including a FY2026 net loss of $105.2M, negative adjusted free cash flow (negative $86M), international price compression (~$21M), legacy U.S. beverage headwinds, and significant working capital tied up in the BrewDog transaction. Overall the company presented a pathway to higher margins and cash generation but still faces execution and market-mix headwinds in the near term.View all TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
$6.13
▲(57.86% Upside)
Technical Analysis
Ownership Overview
1.59% Insiders
0.36% Mutual Funds
0.17% Other Institutional Investors
94.93% Public Companies and Individual Investors